Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 4/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31089969 | 0.81 | GAA (0.36) | CYP4F2CYP4A11DGAT2ATRRXRA | |
| SCHEMBL20765180 | 0.81 | GAA (0.36) | CYP4F2CYP4A11DGAT2ATRRXRA | |
| SCHEMBL20786559 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT2ATR | |
| SCHEMBL23782723 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11DGAT2ATRRXRA | |
| SCHEMBL25171411 | 0.81 | CYP4F2 (0.36) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL29168077 | 0.81 | IDO1 (0.35) | CYP4F2CYP4A11DGAT2RXRARXRB | |
| SCHEMBL20786488 | 0.79 | ATR (0.39) | CYP4F2CYP4A11DGAT2ATR | |
| SCHEMBL20786309 | 0.79 | MAPK1 (0.36) | CYP4F2CYP4A11DGAT2ATR | |
| SCHEMBL6508680 | 0.79 | RET (0.32) | CYP4F2CYP4A11DGAT2ATRRXRA | |
| SCHEMBL30124206 | 0.79 | RET (0.32) | CYP4F2CYP4A11DGAT2ATRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | CYP4F2 3449/4885CYP4A11 3829/4885DGAT2 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.